Method of treating inflammation
Inventors
Chan, Phillip P. • Young, Wei-Tai • Capponi, Vincent J. • Golobish, Thomas D. • Ali, Humayra Begum
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10034894-B2
Publication Date
2018-07-31
Expiration Date
Abstract
The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
Core Innovation
The invention provides a method of treating systemic, regional, or local inflammation in a patient suffering inflammation by administering a therapeutically effective dose of a sorbent for an inflammatory mediator. The inflammatory mediator results from inflammatory bowel disease, burns, exposure to neurotoxins, or sepsis, and the sorbent is a biocompatible polymer intended to act on inflammatory mediators present in the patient.
The sorbent comprises a cross-linked, porous styrene or divinylbenzene copolymer. The biocompatible polymer has a pore structure in which the total pore volume of pore sizes in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer, with additional pore-volume relationships across specified pore diameter ranges.
The disclosed polymer formats and architectures include coated polymers with crosslinking and dispersing agents, hypercrosslinked polystyrene, self-wetting hydrophilic polymers, and polymer variants including ion-exchange and cellulosic variants. In some embodiments, the polymer is configured as porous particles or beads and may be administered in forms such as slurry, powder, beads, tablets, or suppositories.
Claims Coverage
The provided independent claim contains four principal inventive limitations: treating systemic, regional, or local inflammation by administering a therapeutically effective dose of a sorbent for an inflammatory mediator; using a biocompatible polymer that is a cross-linked, porous styrene or divinylbenzene copolymer; requiring a pore structure with a defined total pore volume for pore sizes between 50 Å and 3000 Å; and limiting the inflammation context to inflammatory bowel disease, burns, exposure to neurotoxins, or sepsis.
Therapeutically effective sorbent administration for inflammation
A method of treating systemic, regional, or local inflammation by administering a therapeutically effective dose of a sorbent for an inflammatory mediator to the patient.
Biocompatible cross-linked porous styrene/divinylbenzene copolymer sorbent
The sorbent is a biocompatible polymer that comprises a cross-linked, porous styrene or divinylbenzene copolymer.
Defined pore-volume for pore sizes from 50 Å to 3000 Å
The biocompatible polymer has a pore structure where the total pore volume of pore sizes in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer.
Inflammation arising from inflammatory bowel disease, burns, neurotoxins, or sepsis
The inflammatory mediator results from inflammatory bowel disease, burns to the patient, exposure of the patient to neurotoxins, or sepsis.
The inventive coverage is focused on therapeutically effective dosing of a sorbent polymer that is cross-linked and porous with styrene/divinylbenzene copolymer chemistry, combined with a pore-volume requirement over 50 Å to 3000 Å, and a specified inflammation and mediator source context including inflammatory bowel disease, burns, neurotoxins, or sepsis.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?